Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aptose Biosciences Inc

APTO
Current price
1.27 USD -0.02 USD (-1.55%)
Last closed 1.8 CAD
Sector Healthcare
Industry Biotechnology
Exchange TO
Capitalization 28 263 060 CAD
Yield for 12 month +157.35 %
1Y
3Y
5Y
10Y
15Y
APTO
21.11.2021 - 28.11.2021

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada. Address: 251 Consumers Road, Toronto, ON, Canada, M2J 4R3

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

42.83 CAD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

Key Figures APTO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -52 214 720 CAD
Operating Margin TTM
PE Ratio
Return On Assets TTM -102.23 %
PEG Ratio
Return On Equity TTM -293.96 %
Wall Street Target Price 42.83 CAD
Revenue TTM
Book Value -0.36 CAD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -10.42 CAD
Diluted Eps TTM -10.42 CAD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics APTO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History APTO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:15
Payout Ratio
Last Split Date 06.06.2023
Dividend Date

Stock Valuation APTO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -0.3582
Price Book MRQ 3.3313

Financials APTO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators APTO

For 52 weeks

1.71 CAD 11.39 CAD
50 Day MA 2.26 CAD
Shares Short Prior Month 6 971
200 Day MA 3.7 CAD
Short Ratio 1.63
Shares Short 6 884
Short Percent 0.04 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds


M

MDAXEX

208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics

Metals


Gold

2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics